Biotech Hits 11-Year High On Potential To Dethrone Oxycodone – Investor’s Business Daily

Nektar Therapeutics (NKTR) stock soared more than 40% to an 11-year high Monday after unveiling strong data for a pain-relief pill that could be an alternative to the potentially addictive oxycodone.

In a phase three study of 600 patients, Nektar’s drug, known as NKTR-181, significantly improved chronic low back pain vs. a placebo in patients never treated with an opioid. The trial (more…)

Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone…

TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the U.S. Food and Drug Administration (“FDA“) has accepted for filing the Company’s previously-announced New Drug Application (“NDA”) seeking authorization to market (more…)

Intellipharmaceutics Submits New Drug Application for Rexista … – Nasdaq


TORONTO, Nov. 25, 2016 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA“) seeking authorization to market its Rexista® (more…)